Point72 (Difc) LTD Macrogenics Inc Transaction History

Point72 (Difc) LTD

$2.64 Trillion
Q2 2025

A detailed history of Point72 (Difc) LTD transactions in Macrogenics Inc stock. As of the latest transaction made, Point72 (Difc) LTD holds 190 shares of MGNX stock, worth $368. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190

Holding current value

$368

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2025 Aug 14, 2025	BUY	$1.06 - $1.79 $201 - $340	190 New	190 $230,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $393,262 - $864,210	40,252 New	40,252 $593 Million

Others Institutions Holding MGNX

# of Institutions

117

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

Bellevue Group Ag Kuesnacht, V8

9.92M
Shares

$19.2 Million
0.27% of portfolio
Armistice Capital, LLC New York, NY

5.96M
Shares

$11.6 Million
0.13% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$10.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.21M
Shares

$8.17 Million
0.0% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.25M
Shares

$6.31 Million
0.02% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $119M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 (Difc) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 (Difc) LTD with notifications on news.

Account